For children diagnosed with rheumatic fever, the prospect of monthly penicillin injections is a painful and often traumatic experience. Researchers at Griffith University, in collaboration with the University of New England, are exploring an alternative therapy that could revolutionize treatment for this condition. Their findings, published in mBio, suggest that low-dose interleukin 2 (LD-IL-2) therapy could halt the progression of rheumatic heart disease, offering a more manageable and less painful treatment option.

Rheumatic fever is an inflammatory disease that can develop after a strep throat infection, primarily affecting children. The immune system’s response to the streptococcal infection can trigger an abnormal inflammatory reaction, leading to rheumatic heart disease. Currently, the primary method to prevent the progression of rheumatic heart disease is through monthly penicillin injections, which must be administered for over a decade.

Professor Michael Good from Griffith’s Institute for Biomedicine and Glycomics emphasizes the need for alternatives to monthly penicillin injections due to poor compliance and the potential for IL-2 therapy to be a game-changer. “For school-aged children with rheumatic fever, monthly intramuscular penicillin injections for around 10 years can be painful and traumatic if they have a fear of needles, and some people may have limited access to penicillin or to healthcare facilities,” said Professor Good. “Our proposed approach involves treating patients who are at high risk of developing rheumatic fever, with a five-day course of IL-2 therapy to prevent the abnormal inflammatory responses which could trigger autoimmune reactions and tissue damage.”

In the United States, rheumatic fever is relatively rare, but it remains a significant health issue in certain communities, particularly among Native American populations. The Centers for Disease Control and Prevention (CDC) reports that while the overall incidence of rheumatic fever has declined, it still affects vulnerable groups. The new LD-IL-2 therapy could offer a more sustainable and less invasive treatment option, reducing the burden on both patients and healthcare providers.

Dr. Ailin Lepletier hopes that a single course of LD-IL-2 therapy, given subcutaneously, could replace the need for monthly prophylactic antibiotics. “With the generous support of the Heart Foundation, we are embarking on new studies to investigate whether a single course of low-dose IL-2, given subcutaneously, can elicit long-term immunoregulatory responses capable of preventing recurrent rheumatic fever,” said Dr. Lepletier. “Subcutaneous injections are less painful than intramuscular penicillin needles, and the therapy has the added benefit of ensuring children can maintain regular school attendance without the need for regular hospital or clinic visits.”

Associate Professor Manisha Pandey highlights the urgency of finding an alternative to slow the progression of rheumatic fever to rheumatic heart disease. “The disease burden is most severe in low-income countries and among indigenous peoples in high-income countries, with more than 40 million people affected worldwide,” she said. “Alternative therapies that reduce the need for painful monthly injections will be a major step forward for children and families experiencing rheumatic fever.”

The Heart Foundation National Manager of Population Health and Wellbeing, Le Smith, expressed enthusiasm for the potential of the new therapy. “The Heart Foundation is proud to support advances in research that prevent progression and complications of acute rheumatic fever and rheumatic heart disease, conditions that disproportionately affect indigenous communities in Australia,” he said. “Alternative therapies that reduce the need for painful monthly injections will be a major step forward for children and families experiencing rheumatic fever.”

Studies are planned to commence in February in collaboration with Dr. Rukshan Rafeek and Professor Natkunam Kethesan at the University of New England. The paper ‘Low-dose interleukin 2 therapy halts the progression of post-streptococcal autoimmune complications in a rat model of rheumatic heart disease’ has been published in mBio.

The potential impact of this research extends beyond Australia and the United States. In countries where rheumatic fever remains a significant health issue, the development of a more effective and less invasive treatment could dramatically improve the quality of life for affected children and their families. The research also highlights the importance of ongoing investment in medical research and the development of new therapies to address long-standing health challenges.

While the new therapy shows promise, it is important to acknowledge potential challenges. Ensuring widespread access to LD-IL-2 therapy, particularly in low-income countries and indigenous communities, will require significant investment and infrastructure development. Additionally, further research is needed to fully understand the long-term effects of LD-IL-2 therapy and to optimize its administration.

Despite these challenges, the potential benefits of LD-IL-2 therapy are clear. By reducing the need for painful monthly injections and improving treatment compliance, this new approach could significantly enhance the lives of children with rheumatic fever. As research continues, the hope is that LD-IL-2 therapy will become a standard part of rheumatic fever treatment, offering a more humane and effective solution to a long-standing medical challenge.